The British National Health Services (NHS) has agreed to a oral medicine to treat one of the most advanced forms of breast cancer, in a move described as a "milestone" in the field of disease treatment. The new medicine, "Capifasserete" (also known as Truqap), carries a ghost of about 3000 women annually who suffer from positive breast cancer for hormone receptors (HR+) and the negative f...
[Short citation of 8% of the original article]